ALMS - Alumis Inc.
Alumis Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
As of Aug 14, 2026: spot at $25.02, ATM IV 204.8%, max pain $27.00, net GEX $199.8K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $3.15B
- Beta
- -0.67
- 52-Week Range
- 3.76-31.35
- CEO
- Martin Babler
- Employees
- 225
- IPO Date
- Jun 28, 2024
- Exchange
- NASDAQ
What ALMS Looks Like to Options Traders Today
IV rank of 46.3% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($199.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.151) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The ALMS overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ALMS overview questions
- What is ALMS?
- ALMS is the ticker symbol for Alumis Inc., a listed security. Alumis Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. Listed on NASDAQ. ALMS is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ALMS options snapshot look like today?
- As of Aug 14, 2026, the ALMS options snapshot shows spot at $25.02, ATM IV 204.8%, IV rank 46.3%, max pain $27.00, net GEX $199.8K, expected move 58.71%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ALMS's key statistics?
- Alumis Inc. (ALMS) carries a market capitalization of $3.15B, beta of -0.67 relative to the broader market, 52-week range of 3.76-31.35. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ALMS belong to?
- Alumis Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ALMS's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ALMS data on this page?
- The options snapshot above is dated Aug 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).